Skip to Main Content

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone, and welcome back. Damian here with a look at the year ahead for biotech, plus a long-awaited admission and a remembrance for one of medicine’s true stalwarts.

advertisement

The need-to-know this morning

  • Goldman Sachs Asset Management raised $650 million for a new life sciences fund that will invest in biotech, tools, and diagnostic startups.
  • Agios Pharmaceuticals said its drug, called mitapivat, significantly increased hemoglobin levels compared to a placebo in patients with non-tranfusion-dependent alpha and beta thalassemia. The results achieved the goals of a Phase 3 study.

Welcome back to biotech

In the time since last we sent this newsletter, the banner biotech index closed the year 8% above where it began, a late-year rally driven by yet another billion-dollar deal and the revelation that 2023’s last big catalyst was a major success.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.